Idiopathic Versus Secondary Thrombosis as a Predictive Marker of Occult Malignancy

Antonio Girolami

doi:10.1055/s-0037-1615169

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1998; 80(01): 206-207
DOI: 10.1055/s-0037-1615169

Letters to the Editor

Schattauer GmbH

Idiopathic Versus Secondary Thrombosis as a Predictive Marker of Occult Malignancy

Antonio Girolami

¹Institute of Medical Semeiotics, University of Padua Medical School, Padua, Italy

References
1 Rajan R, Levine M, Gent M, Hirsh J, Geerts W, Skingley P, Julian J. The occurrence of subsequent malignancy in patients presenting with deep vein thrombosis: results from a historical cohort study.. Thromb Haemost 1998; 79: 19-22.
2 Levine MN, Hirsh J, Gent M, Turpie AG, Weitz J, Ginsberg J, Geerts W, LeClerc J, Neemeh J, Powers P, Piovella F. Optimal duration of oral anticoagulant therapy: a randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis.. Thromb Haemost 1995; 74: 606-11.
3 Aderka D, Brown A, Zelikovski A, Pinkhas J. Idiopathic deep vein thrombosis in an apparently healthy patient as a premonitory sign of occult cancer.. Cancer 1986; 57: 1846-9.
4 Monreal M, Salvador R, Soriano V, Sabria M. Cancer and deep vein thrombosis.. Arch Intern Med 1988; 148: 485.
5 Monreal M, Lafoz E, Casals A, Inaraja L, Montserrat E, Callejas JM, Martorellet A. Occult cancer in patients with deep venous thrombosis: a systematic approach.. Cancer 1991; 67: 541-5.
6 Prandoni P, Lensing AWA, Büller HR, Cogo A, Prins MH, Cattelan AM, Cuppini S, Noventa F, ten Cate JW. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer.. N Engl J Med 1992; 327: 1128-33.
7 Monreal M, Casals A, Boix J, Olazabal A, Montserrat E, Ribas Mundo M. Occult cancer in patients with acute pulmonary embolism. A prospective study.. Chest 1993; 103: 816-9.
8 Bastounis EA, Karayannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer in patients with deep venous thrombosis: a prospective study.. J Intern Med 1996; 239: 153-6.
9 Ahmed Z, Mohuddin Z. Deep vein thrombosis as a predictor of cancer.. Angiology 1996; 47: 261-5.
10 Hettiarachchi RJK, Prins MH, Büller HR, Prandoni P, ten Cate JW. Occult malignancy in patients with deep-vein thrombosis. Incidence and risk indicators.. Thromb Haemost 1998 (Suppl.) OC-1563.
11 Achkar A, Laaban JP, Horellou MH, Rabbat A, Conard J, Nataf J. Prospective screening for occult cancer in patients with venous thromboembolism.. Thromb Haemost 1998 (Suppl) OC-1564.
12 Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: which patients, which cancers.. Thromb Haemost 1998; 78: 1316-8.
13 Koopman MMW, Prandoni P, Piovella F, Ockelford PA, Brandjes DPM, van der Meer J, Gallus AS, Simonneau G, Chesterman CH, Prins MH, Bossuyt PMM, de Haes H, van den Belt AGM, Sagnard L, D’Azemar P, Büller HR. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home.. N Engl J Med 1996; 334: 682-7.
14 Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep vein thrombosis.. Ann Intern Med 1996; 125: 785-93.
15 Nordstrom M, Linblad B, Anderson H, Bergqvist D, Kjellstrom T. Deep vein thrombosis and occult malignancy: an epidemiological study.. Mr Med J 1994; 308: 891-4.
16 The Columbus Investigators.. Low-molecular-weight heparin in the treatment of patients with venous thromboembolism.. N Engl J Med 1998; 337: 657-62.
17 Prandoni P. Antithrombotic strategies in patients with cancer.. Thromb Haemost 1998; 78: 141-4.
18 Piccioli A, Lensing AWA, Prandoni P. Screening for occult malignancy in patients with idiopathic venous thromboembolism (SOMIT). Study design.. Thromb Haemost 1998 (Suppl.) PS-489.